PTEN deletion
PTEN deletion
|
Prostate Cancer
Prostate Cancer
|
GSK2636771
Sensitive: C3 – Early Trials
Clin Cancer Res - 2 weeks
|
No biomarker
No biomarker
|
Prostate Cancer
Prostate Cancer
|
enzalutamide
NICE - 3 weeks
|
PTEN deletion
PTEN deletion
|
Prostate Cancer
Prostate Cancer
|
GDC-0068
Sensitive: B - Late Trials
Lancet - 3 weeks
|
No biomarker
No biomarker
|
Prostate Cancer
Prostate Cancer
|
|
No biomarker
No biomarker
|
Prostate Cancer
Prostate Cancer
|
|
No biomarker
No biomarker
|
Prostate Cancer
Prostate Cancer
|
|
BRCA2 mutation
BRCA2 mutation
|
Prostate Cancer
Prostate Cancer
|
|
BRCA1 mutation
BRCA1 mutation
|
Prostate Cancer
Prostate Cancer
|
|
No biomarker
No biomarker
|
Prostate Cancer
Prostate Cancer
|
|
No biomarker
No biomarker
|
Prostate Cancer
Prostate Cancer
|
|
No biomarker
No biomarker
|
Prostate Cancer
Prostate Cancer
|
|
No biomarker
No biomarker
|
Prostate Cancer
Prostate Cancer
|
|
ATM mutation
ATM mutation
|
Prostate Cancer
Prostate Cancer
|
|
No biomarker
No biomarker
|
Prostate Cancer
Prostate Cancer
|
|
BRCA1 mutation
BRCA1 mutation
|
Prostate Cancer
Prostate Cancer
|
|
BRCA2 mutation
BRCA2 mutation
|
Prostate Cancer
Prostate Cancer
|
|
|
Prostate Cancer
Prostate Cancer
|
|
No biomarker
No biomarker
|
Prostate Cancer
Prostate Cancer
|
|
No biomarker
No biomarker
|
Prostate Cancer
Prostate Cancer
|
leuprolide mesylate injectable suspension
|
|
Prostate Cancer
Prostate Cancer
|
pembrolizumab
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Prostate Cancer
Prostate Cancer
|
mitoxantrone
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Prostate Cancer
Prostate Cancer
|
etoposide IV
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Prostate Cancer
Prostate Cancer
|
atezolizumab
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Prostate Cancer
Prostate Cancer
|
docetaxel
Sensitive: A2 - Guideline
|
CDK12 mutation
CDK12 mutation
|
Prostate Cancer
Prostate Cancer
|
olaparib
Sensitive: A2 - Guideline
|
PALB2 mutation
PALB2 mutation
|
Prostate Cancer
Prostate Cancer
|
olaparib
Sensitive: A2 - Guideline
|
CHEK2 mutation
CHEK2 mutation
|
Prostate Cancer
Prostate Cancer
|
olaparib
Sensitive: A2 - Guideline
|
CHEK1 mutation
CHEK1 mutation
|
Prostate Cancer
Prostate Cancer
|
olaparib
Sensitive: A2 - Guideline
|
AR splice variant 7
AR splice variant 7
|
Prostate Cancer
Prostate Cancer
|
abiraterone acetate
Resistant: A2 - Guideline
|
AR splice variant 7
AR splice variant 7
|
Prostate Cancer
Prostate Cancer
|
enzalutamide
Resistant: A2 - Guideline
|
RAD51B mutation
RAD51B mutation
|
Prostate Cancer
Prostate Cancer
|
olaparib
Sensitive: A2 - Guideline
|
RAD51C mutation
RAD51C mutation
|
Prostate Cancer
Prostate Cancer
|
olaparib
Sensitive: A2 - Guideline
|
RAD51D mutation
RAD51D mutation
|
Prostate Cancer
Prostate Cancer
|
olaparib
Sensitive: A2 - Guideline
|
RAD54L mutation
RAD54L mutation
|
Prostate Cancer
Prostate Cancer
|
olaparib
Sensitive: A2 - Guideline
|
FANCL mutation
FANCL mutation
|
Prostate Cancer
Prostate Cancer
|
olaparib
Sensitive: A2 - Guideline
|
BRIP1 mutation
BRIP1 mutation
|
Prostate Cancer
Prostate Cancer
|
olaparib
Sensitive: A2 - Guideline
|
BARD1 mutation
BARD1 mutation
|
Prostate Cancer
Prostate Cancer
|
olaparib
Sensitive: A2 - Guideline
|
PPP2R2A mutation
PPP2R2A mutation
|
Prostate Cancer
Prostate Cancer
|
olaparib
Resistant: A2 - Guideline
|
No biomarker
No biomarker
|
Prostate Cancer
Prostate Cancer
|
sipuleucel-T
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Prostate Cancer
Prostate Cancer
|
histrelin acetate + nilutamide
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Prostate Cancer
Prostate Cancer
|
bicalutamide + goserelin acetate
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Prostate Cancer
Prostate Cancer
|
goserelin acetate + flutamide
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Prostate Cancer
Prostate Cancer
|
goserelin acetate + nilutamide
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Prostate Cancer
Prostate Cancer
|
triptorelin
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Prostate Cancer
Prostate Cancer
|
leuprolide acetate
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Prostate Cancer
Prostate Cancer
|
goserelin acetate
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Prostate Cancer
Prostate Cancer
|
abiraterone acetate + degarelix
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Prostate Cancer
Prostate Cancer
|
abiraterone acetate + triptorelin
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Prostate Cancer
Prostate Cancer
|
abiraterone acetate + leuprolide acetate
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Prostate Cancer
Prostate Cancer
|
abiraterone acetate + histrelin acetate
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Prostate Cancer
Prostate Cancer
|
abiraterone acetate + goserelin acetate
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Prostate Cancer
Prostate Cancer
|
bicalutamide + triptorelin
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Prostate Cancer
Prostate Cancer
|
triptorelin + flutamide
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Prostate Cancer
Prostate Cancer
|
triptorelin + nilutamide
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Prostate Cancer
Prostate Cancer
|
leuprolide acetate + bicalutamide
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Prostate Cancer
Prostate Cancer
|
leuprolide acetate + flutamide
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Prostate Cancer
Prostate Cancer
|
leuprolide acetate + nilutamide
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Prostate Cancer
Prostate Cancer
|
bicalutamide + histrelin acetate
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Prostate Cancer
Prostate Cancer
|
histrelin acetate + flutamide
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Prostate Cancer
Prostate Cancer
|
carboplatin + docetaxel
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Prostate Cancer
Prostate Cancer
|
carboplatin + etoposide oral
Sensitive: A2 - Guideline
|
No biomarker
No biomarker
|
Prostate Cancer
Prostate Cancer
|
cisplatin + etoposide oral
Sensitive: A2 - Guideline
|
AR amplification
AR amplification
|
Prostate Cancer
Prostate Cancer
|
enzalutamide
Resistant: B - Late Trials
|
BRCA1 mutation
BRCA1 mutation
|
Prostate Cancer
Prostate Cancer
|
niraparib
Sensitive: B - Late Trials
|
BRCA2 mutation
BRCA2 mutation
|
Prostate Cancer
Prostate Cancer
|
niraparib
Sensitive: B - Late Trials
|
No biomarker
No biomarker
|
Prostate Cancer
Prostate Cancer
|
CYP17A1 inhibitor
Sensitive: B - Late Trials
|
No biomarker
No biomarker
|
Prostate Cancer
Prostate Cancer
|
RV001
Sensitive: B - Late Trials
|
PTEN mutation
PTEN mutation
|
Prostate Cancer
Prostate Cancer
|
bicalutamide
Sensitive: B - Late Trials
|
|
Prostate Cancer
Prostate Cancer
|
GDC-0068 + AST-2970 + prednisolone
Sensitive: B - Late Trials
|
No biomarker
No biomarker
|
Prostate Cancer
Prostate Cancer
|
EPI-7386
Sensitive: B - Late Trials
|
No biomarker
No biomarker
|
Prostate Cancer
Prostate Cancer
|
ipilimumab
Sensitive: B - Late Trials
|
AR amplification
AR amplification
|
Prostate Cancer
Prostate Cancer
|
AST-2970
Resistant: B - Late Trials
|
TP53 deletion
TP53 deletion
|
Prostate Cancer
Prostate Cancer
|
abiraterone acetate
Resistant: B - Late Trials
|
TP53 deletion
TP53 deletion
|
Prostate Cancer
Prostate Cancer
|
enzalutamide
Resistant: B - Late Trials
|
RB1 deletion
RB1 deletion
|
Prostate Cancer
Prostate Cancer
|
abiraterone acetate
Resistant: B - Late Trials
|
RB1 deletion
RB1 deletion
|
Prostate Cancer
Prostate Cancer
|
enzalutamide
Resistant: B - Late Trials
|
BRCA2 deletion
BRCA2 deletion
|
Prostate Cancer
Prostate Cancer
|
enzalutamide
Sensitive: B - Late Trials
|
BRCA2 deletion
BRCA2 deletion
|
Prostate Cancer
Prostate Cancer
|
abiraterone acetate
Sensitive: B - Late Trials
|
BRCA1 positive
BRCA1 positive
|
Prostate Cancer
Prostate Cancer
|
olaparib
Sensitive: B - Late Trials
|
BRCA2 positive
BRCA2 positive
|
Prostate Cancer
Prostate Cancer
|
olaparib
Sensitive: B - Late Trials
|
ATM positive
ATM positive
|
Prostate Cancer
Prostate Cancer
|
olaparib
Sensitive: B - Late Trials
|
PTEN negative
PTEN negative
|
Prostate Cancer
Prostate Cancer
|
GDC-0068
Sensitive: B - Late Trials
|
FOLH1 positive
FOLH1 positive
|
Prostate Cancer
Prostate Cancer
|
177 Lu PSMA-617
Sensitive: B - Late Trials
|
No biomarker
No biomarker
|
Prostate Cancer
Prostate Cancer
|
177 Lu PSMA-617
Sensitive: B - Late Trials
|
PD-L1 expression
PD-L1 expression
|
Prostate Cancer
Prostate Cancer
|
pembrolizumab
Sensitive: C1 - Off-label
|
PD-L1 expression
PD-L1 expression
|
Prostate Cancer
Prostate Cancer
|
durvalumab
Sensitive: C1 - Off-label
|
|
Prostate Cancer
Prostate Cancer
|
nivolumab
Sensitive: C1 - Off-label
|
BRCA2 mutation
BRCA2 mutation
|
Prostate Cancer
Prostate Cancer
|
talazoparib
Sensitive: C1 - Off-label
|
PD-L1 expression
PD-L1 expression
|
Prostate Cancer
Prostate Cancer
|
nivolumab + ipilimumab
Sensitive: C1 - Off-label
|
BRCA1 mutation
BRCA1 mutation
|
Prostate Cancer
Prostate Cancer
|
talazoparib
Sensitive: C1 - Off-label
|
ATM mutation
ATM mutation
|
Prostate Cancer
Prostate Cancer
|
talazoparib
Sensitive: C2 – Inclusion Criteria
|
PD-L1 expression
PD-L1 expression
|
Prostate Cancer
Prostate Cancer
|
nivolumab
Sensitive: C2 – Inclusion Criteria
|
|
Prostate Cancer
Prostate Cancer
|
nivolumab + ipilimumab
Sensitive: C2 – Inclusion Criteria
|
CDK12 mutation
CDK12 mutation
|
Prostate Cancer
Prostate Cancer
|
nivolumab
Sensitive: C2 – Inclusion Criteria
|
FANCA mutation
FANCA mutation
|
Prostate Cancer
Prostate Cancer
|
rucaparib
Sensitive: C2 – Inclusion Criteria
|
